Scalable EPSC-iMSC EVs for Pulmonary Fibrosis

2026-08-16

Gong et al. developed a bioreactor-based platform that combines EPSC-derived induced mesenchymal stem cells with continuous extracellular vesicle harvesting. The system produced standardized iMSC-EVs at high yield and retained therapeutic activity in a bleomycin-induced pulmonary fibrosis model, offering a practical framework for more reproducible EV manufacturing.

PSMD14–CARM1 Signaling in Hepatocellular Carcinoma

2026-08-15

This study identifies a PSMD14–CARM1–FERMT1 signaling axis that promotes hepatocellular carcinoma proliferation and metastasis. Its combination of clinical data, cellular and animal models, epigenetic analysis, and pharmacologic validation supports CARM1 as a mechanistically relevant therapeutic target while highlighting the need to distinguish direct CARM1 inhibition from broader protease inhibition strategies.

Artesunate: From Mechanism to Translation

2026-08-14

Artesunate is more than an artemisinin derivative with cytotoxic activity. Its intersecting effects on ferroptosis, AKT/mTOR signaling, and caspase-11-mediated pyroptosis create an opportunity to redesign how translational researchers measure cancer drug responses. This article connects mechanistic validation with assay strategy, model selection, formulation, and decision-making in small cell lung carcinoma research and esophageal squamous cell carcinoma models.

Atorvastatin and Ferroptosis in Hepatocellular Carcinoma

2026-08-14

This 2025 study integrates ferroptosis-related transcriptomics, survival modeling, and Connectivity Map screening to develop a four-gene prognostic signature for hepatocellular carcinoma and identify Atorvastatin as a candidate treatment. In vitro and in vivo validation supports an association between Atorvastatin exposure, ferroptosis induction, and reduced HCC growth and migration, while the findings remain preclinical.

Zoledronic Acid: From Apoptosis to Translation

2026-08-13

A translational framework for using Zoledronic Acid to connect cancer-cell apoptosis, myeloma biology, and osteolytic bone disease research with more decision-ready experimental designs.

Deferasirox for Iron and Lysosome Stress Assays

2026-08-13

Deferasirox is an oral iron chelator that gives researchers a practical way to perturb Fe³⁺ availability while studying nutrient stress, mitochondrial ROS, and lysosome-dependent cell death. This workflow connects iron metabolism assays with the TCF25–V-ATPase pathway described in recent Cell Reports research, while clearly separating established findings from testable hypotheses.

Proteasome Control in Viral Inflammation Research

2026-08-12

A translational framework for using Clasto-Lactacystin β-lactone to connect proteasome activity with viral immune evasion, necroptosis, cancer research, and disease-model design.

Resazurin Sodium Salt for Bone-Cell Viability

2026-08-12

Resazurin sodium salt converts cellular redox activity into a practical fluorescence readout for osteoblast workflows, cytotoxicity studies, and high-throughput screening. This guide connects the assay to recent porcupine-inhibition research while emphasizing controls, fresh reagent preparation, and orthogonal validation.

Amphotericin B: Applied Assay Workflows

2026-08-11

Build reproducible fungal membrane, host-cell toxicity, and immune-signaling assays around a single mechanistic perturbation. This guide combines concentration planning, orthogonal readouts, and a reference-informed workflow for using Amphotericin B in fungal infection research.

miR-18a, ALOXE3, and Ferroptosis in Glioblastoma

2026-08-11

DiR for EV Tracking and MPS Evasion Strategy

2026-08-10

Extracellular vesicle therapies are constrained by rapid mononuclear phagocyte system clearance, making biodistribution a central translational challenge. This thought-leadership article explains how DiR (DiIC 18 (7)) can support mechanistically informed EV tracking, validate “Engage & Evasion” strategies, and strengthen the bridge between membrane biology, imaging, and therapeutic development.

NADH Reductive Stress in Disease Models

2026-08-09

NADH is more than an ATP-associated cofactor: its balance with NAD⁺ can reveal mitochondrial reductive stress and disease biology. This evidence-led guide connects LC-MS/MS measurement, model selection, and research applications from Leigh syndrome to photocatalytic cancer therapy.

2-Chloroethanol Drives A1 Astrocyte–Microglia Signaling

2026-08-08

The reference study identifies astrocytes as an early cellular target of 2-chloroethanol, a metabolite of 1,2-dichloroethane, and describes how ROS-dependent p38 MAPK, NF-κB, and AP-1 signaling promotes an A1-like inflammatory state. Its findings support a model in which astrocyte-derived IL-1β and TNF-α, rather than direct toxicant exposure alone, drive M1 microglial polarization and neuroinflammation.

Thiamet G: Reliable O-GlcNAc Assay Workflows

2026-08-07

Learn how Thiamet G (SKU B2048) can support controlled O-GlcNAc modulation in viability, proliferation, cytotoxicity, tauopathy, leukemia, and placental stress studies. This scenario-based guide covers assay compatibility, dose selection, interpretation, storage, and practical product-selection criteria.

O-GlcNAcylation Regulates HUWE1-TfR1 Axis in Preeclampsia Fe

2026-08-07

This study uncovers how O-GlcNAc modification of HUWE1 enhances ubiquitination and degradation of transferrin receptor 1, restraining ferroptosis and supporting trophoblast syncytialization in preeclampsia. The findings establish the O-GlcNAc–HUWE1–TfR1 pathway as a mechanistic link between iron metabolism and placental dysfunction, and highlight potential molecular targets for therapeutic intervention.